PG
Highly rated in
32
conditions
Highly rated in
32
conditions
Check Dr. Pierre M. Giglio's experience treating your condition:
About Dr. Pierre M. Giglio

Pierre Giglio is a Neurologist in Columbus, Ohio. Giglio has been practicing medicine for over 29 years and is highly rated in 32 conditions, according to our data. His top areas of expertise are Glioma, Glioblastoma, Astrocytoma, and Brain Tumor. He is licensed to treat patients in Ohio. Giglio is currently accepting new patients.

His clinical research consists of co-authoring 59 peer reviewed articles and participating in 12 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Pierre M. Giglio it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. Pierre M. Giglio accepts the following insurance:

  •  Ambetter
  •  Molina Healthcare
  •  CareSource
  •  Buckeye Health

Call to see if your plan is accepted.
Locations
300 W 10th Ave, Columbus, OH 43210
Background & Education
Graduate Institution
Other, 1993
Specialties
Neurology
Licenses
Psychiatry & Neurology in OH
Hospital Affiliations
Ohio State University Brain And Spine Hospital
The James Cancer Hospital And Solove Research Institute
Ohio State University Wexner Medical Center
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


12 Clinical Trials

Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
A Phase II Trial of AZD9291 (Osimertinib) With or Without Bevacizumab in Patients With EGFR Mutation Positive NSCLC and Brain Metastases
The Correlation Between the Genetic and Neuroimaging Signatures in Newly Diagnosed Glioblastoma
A Phase 2 Trial for Patients With Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide, and BMX-001
Phase 2 Dose-Escalation Study of TPI 287 in Combination With Bevacizumab in Adults With Recurrent or Progressive Glioblastoma Following a Bevacizumab-Containing Regimen
A Randomized Phase 2 Trial of Cediranib and Olaparib Compared to Bevacizumab in Patients With Recurrent Glioblastoma Who Have Not Received Prior VEGF Therapy
View 9 Less Clinical Trials -

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors